Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma

J Neurol. 2002 Aug;249(8):1055-7. doi: 10.1007/s00415-002-0794-1.

Abstract

Six patients with recurrent or progressive anaplastic oligodendroglial tumors after surgical treatment and irradiation were treated with six/seven cycles of intensified PCV: Vincristine (1 mg/m(2)), CCNU (50 mg/m(2)) d.1,15 and procarbazine (75 mg/m(2)) d.2 to 29. If leukocytopenia (< 2.500/microl) or thrombocytopenia (< 75.000/microl) developed, 1 x 10(6) CD34(+) autologous stem cells/ kg body weight were reinfused three days after completion of subsequent cycles. Complete response was seen in 2/6 and partial response in 4/6 patients. Median follow up from time of recurrence was 35 months, progression free survival was 18 to > 39 months and overall survival 23 to > 39 months. We conclude that intensified PCV with stem cell support is feasable in recurrent/progressive anaplastic oligodendroglial tumors and appears to be sufficiently well tolerated to allow further study.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Diseases / prevention & control
  • Brain Neoplasms / drug therapy*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukopenia / chemically induced
  • Leukopenia / therapy
  • Lomustine / adverse effects*
  • Lomustine / therapeutic use*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Oligodendroglioma / drug therapy*
  • Procarbazine / adverse effects*
  • Procarbazine / therapeutic use*
  • Salvage Therapy
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / therapy
  • Treatment Outcome
  • Vincristine / adverse effects*
  • Vincristine / therapeutic use*

Substances

  • Procarbazine
  • Vincristine
  • Lomustine

Supplementary concepts

  • PCV protocol